A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease (PROPEL)

A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01808391

Enrollment

1204

Registered

2013-03-11

Start date

2013-03-31

Completion date

2016-04-30

Last updated

2017-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Drug-eluting Stent

Keywords

Coronary artery disease, Heart disease, Myocardial ischemia, Cardiovascular disease, Arteriosclerosis, Vascular disease

Brief summary

This is a prospective, multicenter, historical controlled study. The present clinical study will measure non-inferiority of 12 month TLF rate compared to historical control.The selected historical control is the Xience V arm from RESOLUTE All-Comer clinical study, that study is a prospective, multicenter, randomized, two-arm, international, open-label study.The historical control did not have angiographic follow up before 12 months, in the present clinical study, only subjects with clinical follow-up conducted at 12 months without any pre-specified angiographic assessment prior to 12 month clinical follow-up will be part of this analysis cohort. Out of the total 1200 patients, 900 patients (clinical follow-up cohort) will be included in this analysis cohort.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients aged 20 years or older. * Patients with symptomatic coronary disease. * Patients with a clinical indication for PCI and stenting of at least one coronary lesion, visually confirmed on coronary angiography. * Patients who give informed consent to participate in this clinical study and sign the informed consent form approved by the institutional review board of each study site before the index PCI. * Patients who agree to undergo all clinical follow-up procedures specified in the protocol for this clinical study. * Patients in whom more than 50% occlusion or stenosis is visually confirmed in a native coronary artery with a diameter of 2.5 mm - 3.5 mm on coronary angiography and that has an anatomical structure suitable for PCI using Resolute Integrity zotarolimus-eluting stent.

Exclusion criteria

* Patients aged 85 years or older. * Patients with cardiogenic shock. * Patients who are pregnant or possibly pregnant. * Patients who cannot comply with the antiplatelet therapy specified for this clinical study. * Patients scheduled to undergo elective surgery within 6 months post-index PCI. * Patients with a history of allergic reaction or hypersensitivity to zotarolimus, sirolimus, tacrolimus, everolimus, or other analogues or derivatives. * Patients with an allergic reaction to antiplatelet or anticoagulant drugs, such as heparin, aspirin, ticlopidine, or clopidogrel, or contrast agents, or those who cannot tolerate these substances and to whom appropriate treatments cannot be given. * Patients with hypersensitivity to cobalt, nickel, chrome, molybdenum, coated polymer (e.g., BioLinx) contained in the materials of the study device or in whom these substances are specifically contraindicated. * Patients who are currently participating in a clinical study of another drug or medical device and in whom assessment of the primary endpoint of that study has not been completed or clinically interferes with the endpoints of this clinical study.

Design outcomes

Primary

Measure	Time frame	Description
TLF (target lesion failure)	12 months	The composite of Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel) or Target Lesion Revascularization (TLR; clinically indicated) (= device oriented endpoint).

Secondary

Measure	Time frame	Description
Delivery success	stent implantation until hospital discharge (average 1-5 days)	Complete passage of the stent across the target lesion with full expansion of the stent to the desired diameter at the desired location. Note: Failed delivery: failure to pass the stent through the guiding catheter into the coronary artery,failure to pass it completely across the target lesion, or failure to expand the stent to its desired diameter. Failed delivery includes proximal deployment defined as those instances of failed delivery when the stent could be advanced only partially across the target lesion but was deployed nonetheless by full expansion.
Lesion success	stent implantation until hospital discharge (average 1-5 days)	Lesion success defined as the attainment of a less than 50% residual stenosis by any percutaneous method.
TLF (target lesion failure)	30 days, 6, 9, 12, 24 and 36 months after index PCI	The composite of Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel) or Target Lesion Revascularization (TLR; clinically indicated) (= device oriented endpoint).
TVF (target vessel failure)	30 days, 6, 9, 12, 24 and 36 months after index PCI	The composite of cardiac death, target vessel myocardial infarction, or clinically-driven target vessel revascularization by percutaneous or surgical methods.
MACE (major adverse cardiac event)	30 days, 6, 9, 12, 24 and 36 months after index PCI	All-cause death, myocardial infarction (QWMI and NQWMI), emergency coronary artery bypass graft(CABG), or TLR by medical or surgical procedure.
Cerebrovascular accident	30 days, 6, 9, 12, 24 and 36 months afetr index PCI	1. Neurological disorder that appears rapidly and persists for at least 24 hours, and is attributable to a reduction in the cerebrovascular blood flow due to bleeding or ischemia. 2. If an AE due to CVA occurs, it is desirable to obtain diagnostic imaging findings constituting evidence or a diagnosis by a specialist. 3. TIA of which the symptoms disappear within 24 hours is not CVA.
Procedure success	stent implantation until hospital discharge (average 1-5 days)	The attainment of \< 50%, residual stenosis of the target lesion and no in-hospital MACE as reported by the physician.
Stent thrombosis	30 days, 6, 9, 12, 24 and 36 months after index PCI	Incidence of ARC-defined definite and probable stent thrombosis, and the combined incidence of definite/probable stent thrombosis.
Duration of dual antiplatelet therapy	12, 24 and 36 months after index PCI	Duration of DAPT after index PCI including the reason for interruption and discontinuation.

Other

Measure	Time frame	Description
Comparison of long-term clinical outcomes due to a difference in follow-up procedure (clinical follow-up or routine angiographic follow-up) after index PCI.	24 months after index PCI	—
Evaluation of medical economics	24 months after index PCI	The objectives of this clinical study are to 1) assess the efficacy and safety of RI-ZES at 10 and 22 months (±60 days) after index PCI for routine angiographic FU after index PCI and to 2) investigate its medical costs.

Countries

Japan

Outcome results